NO170726C - Analogifremgangsmaate ved fremstilling av terapeutisk aktive quinolinderivater - Google Patents

Analogifremgangsmaate ved fremstilling av terapeutisk aktive quinolinderivater

Info

Publication number
NO170726C
NO170726C NO864247A NO864247A NO170726C NO 170726 C NO170726 C NO 170726C NO 864247 A NO864247 A NO 864247A NO 864247 A NO864247 A NO 864247A NO 170726 C NO170726 C NO 170726C
Authority
NO
Norway
Prior art keywords
preparation
therapeutic active
analogy procedure
quinolin derivatives
quinolin
Prior art date
Application number
NO864247A
Other languages
English (en)
Norwegian (no)
Other versions
NO864247L (no
NO170726B (no
NO864247D0 (no
Inventor
Jun-Ichi Matsumoto
Teruyuki Miyamoto
Hiroshi Egawa
Shinichi Nakamura
Original Assignee
Dainippon Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dainippon Pharmaceutical Co filed Critical Dainippon Pharmaceutical Co
Publication of NO864247D0 publication Critical patent/NO864247D0/no
Publication of NO864247L publication Critical patent/NO864247L/no
Priority to NO920721A priority Critical patent/NO173993C/no
Publication of NO170726B publication Critical patent/NO170726B/no
Publication of NO170726C publication Critical patent/NO170726C/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C07D215/56Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
NO864247A 1985-10-29 1986-10-23 Analogifremgangsmaate ved fremstilling av terapeutisk aktive quinolinderivater NO170726C (no)

Priority Applications (1)

Application Number Priority Date Filing Date Title
NO920721A NO173993C (no) 1985-10-29 1992-02-24 Analogifremgangsmaate ved fremstilling av terapeutisk aktivt kinolinderivat

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP24225785 1985-10-29
JP28532385 1985-12-17
JP3262786 1986-02-17

Publications (4)

Publication Number Publication Date
NO864247D0 NO864247D0 (no) 1986-10-23
NO864247L NO864247L (no) 1987-04-30
NO170726B NO170726B (no) 1992-08-17
NO170726C true NO170726C (no) 1992-11-25

Family

ID=27287785

Family Applications (1)

Application Number Title Priority Date Filing Date
NO864247A NO170726C (no) 1985-10-29 1986-10-23 Analogifremgangsmaate ved fremstilling av terapeutisk aktive quinolinderivater

Country Status (26)

Country Link
US (1) US4795751A (zh)
EP (2) EP0221463B1 (zh)
JP (2) JPS62277362A (zh)
KR (1) KR910006806B1 (zh)
CN (1) CN1009930B (zh)
AR (3) AR242031A1 (zh)
AT (2) ATE109472T1 (zh)
AU (1) AU594983B2 (zh)
CA (1) CA1340402C (zh)
DE (3) DE10075028I2 (zh)
DK (2) DK170593B1 (zh)
ES (2) ES2057197T3 (zh)
FI (1) FI87457C (zh)
GE (1) GEP19960467B (zh)
GR (1) GR3002475T3 (zh)
HU (1) HU200452B (zh)
IL (1) IL80404A (zh)
LU (2) LU88596I2 (zh)
MY (1) MY100574A (zh)
NL (2) NL970020I2 (zh)
NO (1) NO170726C (zh)
NZ (1) NZ218089A (zh)
PH (1) PH22862A (zh)
PT (1) PT83643B (zh)
SU (2) SU1635898A3 (zh)
YU (3) YU46414B (zh)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4977154A (en) * 1985-12-12 1990-12-11 Warner-Lambert Company 5-amino and 5-hydroxy-6-fluoroquinolones as antibacterial agents
EP0242789A3 (en) * 1986-04-25 1990-09-05 Dainippon Pharmaceutical Co., Ltd. Novel quinoline derivates and processes for preparation thereof
DE3711193A1 (de) * 1987-04-02 1988-10-13 Bayer Ag 5-substituierte chinolon- und naphthyridoncarbonsaeure-derivate
US5563138A (en) * 1987-04-16 1996-10-08 Otsuka Pharmaceutical Company, Limited Benzoheterocyclic compounds
US4780468A (en) * 1987-08-07 1988-10-25 Warner-Lambert Company 8-trifluoromethyl quinolones as antibacterial agents
US5164392A (en) * 1987-10-16 1992-11-17 Dainippon Pharmaceutical Co., Ltd. Quinoline derivatives and antibacterial agent containing them
IL88003A (en) * 1987-10-16 1992-11-15 Dainippon Pharmaceutical Co Quinoline derivatives,their preparation and pharmaceutical compositions containing them
AU609974B2 (en) * 1988-05-18 1991-05-09 Warner-Lambert Company Improved process for the preparation of 5-amino-7- (substituted amino)-quinoline-3-carboxylic acids
JPH0674261B2 (ja) * 1988-06-21 1994-09-21 塩野義製薬株式会社 キノロンカルボン酸誘導体
JP2709604B2 (ja) * 1988-06-29 1998-02-04 大日本製薬株式会社 マイコプラズマ汚染の防止または除去
US5262417A (en) * 1988-12-06 1993-11-16 The Upjohn Company Antibacterial quinolone compounds
FR2655545B1 (fr) 1989-12-11 1994-06-10 Rhone Poulenc Sante Nouvelle application therapeutique des derives des fluoroquinolones.
DE4019023A1 (de) * 1990-06-14 1991-12-19 Bayer Ag Verfahren zur herstellung von chinolincarbonsaeuren
JP2613139B2 (ja) * 1990-07-19 1997-05-21 エスエス製薬 株式会社 キノロンカルボン酸誘導体
US5342846A (en) * 1990-12-05 1994-08-30 Synphar Laboratories, Inc. 7-substituted-6-fluoro-1,4-dihydro-4-oxo-quinoline-3-carboxylic acid compounds and 7-(substituted triazolyl pyrrolidin-1-yl) 4-oxoquinoline-3-carboxylic acid derivatives useful as antibacterial agents
FR2681863B1 (fr) * 1991-09-27 1995-02-03 Rhone Dpc Europ Solution de sparfloxacine sa preparation et sel la constituant.
CA2102196A1 (en) * 1992-05-26 1993-11-27 Terumitsu Kaihoh 5-aminoquinolone carboxylic acid derivative and antibacterial agent containing the same as active ingredient
WO1993025545A1 (en) * 1992-06-09 1993-12-23 Korea Research Institute Of Chemical Technology Novel quinoline derivatives and processes for preparing the same
US5290794A (en) * 1992-10-27 1994-03-01 Warner Lambert Co. Soluble calcium lactate antibacterial complexes as non-irritating parenteral forms
US5646163A (en) * 1992-10-30 1997-07-08 The Procter & Gamble Company Quinolone 5-(N-heterosubstituted amino) antimicrobials
CN1038326C (zh) * 1993-07-20 1998-05-13 爱斯制药株式会社 5-氨基喹诺酮羧酸衍生物及其含有该衍生物作为活性成分的抗菌剂
US5532239A (en) * 1993-08-02 1996-07-02 Assistance Publique - Hopitaux De Paris Therapeutic application of fluoroquinolone derivatives
EP1135132A2 (en) 1998-12-04 2001-09-26 Influx, Inc. Inhibitors of multidrug transporters
JP4694669B2 (ja) 1999-03-17 2011-06-08 第一三共株式会社 医薬組成物
CN1091103C (zh) * 1999-04-02 2002-09-18 中国科学院上海药物研究所 一类喹诺酮类化合物及它的制备和其用途
US6957105B2 (en) * 2002-03-26 2005-10-18 Cardiac Pacemakers, Inc. Method and apparatus for detecting oscillations in cardiac rhythm with electrogram signals
KR100519158B1 (ko) * 2002-12-21 2005-10-06 주식회사유한양행 퀴놀론 카르복실레이트 유도체의 제조방법
US20070196398A1 (en) * 2006-02-17 2007-08-23 Murthy Yerramilli V S Fluoroquinolone fatty acid salt compositions
US20070197548A1 (en) * 2006-02-17 2007-08-23 Murthy Yerramilli V S Fluoroquinolone compositions
US7973022B2 (en) 2006-02-17 2011-07-05 Idexx Laboratories, Inc. Fluoroquinolone carboxylic acid salt compositions
US20080139574A1 (en) 2006-11-30 2008-06-12 Cadila Healthcare Limited Novel quinoline derivatives
EP3641747B1 (en) 2017-06-22 2023-09-06 Cipla Limited Par-4 secretagogues for the treatment of cancer
CN112870196B (zh) * 2019-11-11 2022-02-18 山东畜牧兽医职业学院 一种治疗耐药性微生物菌的组合物

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3753993A (en) * 1971-05-17 1973-08-21 Sterling Drug Inc 1,4-dihydro-4-oxo-7-pyridyl-3-quinoline-carboxylic acid derivatives
DE3033157A1 (de) * 1980-09-03 1982-04-01 Bayer Ag, 5090 Leverkusen 7-amino-1-cyclopropyl-4-oxo-1,4-dihydro-naphthyridin-3-carbonsaeuren, verfahren zu ihrer herstellung sowie diese enthaltende antibakterielle mittel
JPS58174367A (ja) 1982-04-07 1983-10-13 Tanabe Seiyaku Co Ltd キノリン誘導体及びその製法
DE3248507A1 (de) * 1982-12-29 1984-07-05 Bayer Ag, 5090 Leverkusen Mikrobizide mittel auf chinoloncarbonsaeure basis
DE3248506A1 (de) 1982-12-29 1984-07-05 Bayer Ag, 5090 Leverkusen 1-cyclopropyl-6-fluor-1,4-dihydro-4-oxo-7(alkyl-1-piperazinyl)-3-chinolincarbonsaeuren, verfahren zu ihrer herstellung sowie diese enthaltende antibakterielle mittel
DE3306771A1 (de) * 1983-02-25 1984-08-30 Bayer Ag, 5090 Leverkusen Chinoloncarbonsaeuren, verfahren zu ihrer herstellung sowie diese enthaltende antibakterielle mittel
DE3318145A1 (de) * 1983-05-18 1984-11-22 Bayer Ag, 5090 Leverkusen 7-amino-1-cyclopropyl-6,8-difluor-1,4-dihydro-4-oxo-3-chinolincarbonsaeuren, verfahren zu ihrer herstellung sowie diese enthaltende antibakterielle mittel
CS274601B2 (en) * 1983-07-27 1991-09-15 Dainippon Pharmaceutical Co Method of 1,8-naphthyridine derivative production
JPS60169475A (ja) * 1984-02-14 1985-09-02 Dai Ichi Seiyaku Co Ltd キノリン誘導体
EP0160578B1 (en) 1984-02-17 1989-11-23 Daiichi Seiyaku Co., Ltd. 1,8-naphthyridine derivatives
US4571396A (en) * 1984-04-16 1986-02-18 Warner-Lambert Company Antibacterial agents
ZA852369B (en) 1984-04-26 1985-12-24 Abbott Lab Quinoline antibacterial compounds
DE3420798A1 (de) * 1984-06-04 1985-12-05 Bayer Ag, 5090 Leverkusen 7-(3-aryl-l-piperazinyl)- sowie 7-(3-cyclohexyl-l-piperazinyl)-3-chinoloncarbonsaeuren
DE3420743A1 (de) * 1984-06-04 1985-12-05 Bayer Ag, 5090 Leverkusen 7-amino-1-cyclopropyl-6,8-dihalogen-1,4-dihydro-4-oxo-3-chinolincarbonsaeuren, verfahren zu ihrer herstellung sowie diese enthaltende antibakterielle mittel
JPS6110574A (ja) * 1984-06-25 1986-01-18 Hokuriku Seiyaku Co Ltd 6−フルオロ−1,4−ジヒドロ−4−オキソ−7−置換ピペラジニルキノリン−3−カルボン酸誘導体
IE58742B1 (en) 1984-07-20 1993-11-05 Warner Lambert Co Substituted-9-fluoro-3-methyl-7-oxo-2,3-dihydro-7h-pyrido[1,2,3-de] [1,4]benzoxauine-6-carboxylic acids; sibstituted-5-amino-6-6fluoro-4-oxo.1,4-dihydroquinoline-3 carboxylic acids; substituted-5-amino-6-fluoro-1,4-dihydro-4-oxo-1.8-naphthyridine-3-carboxylic acids; derivatives thereof; pharmaceutical compositions comprising the compounds; and processes for producing the compounds
JPS6191183A (ja) * 1984-10-11 1986-05-09 Kyorin Pharmaceut Co Ltd キノロンカルボン酸誘導体
EP0181521A1 (en) * 1984-10-19 1986-05-21 Otsuka Pharmaceutical Co., Ltd. Antimicrobial 1-substituted Phenyl-4-oxoquinoline-3-carboxylic acid compounds
US4636506A (en) * 1984-12-06 1987-01-13 Pfizer, Inc. 7-heterocyclic-1,4-dihydroquinolones
JPS6212760A (ja) * 1984-12-14 1987-01-21 Dai Ichi Seiyaku Co Ltd 1−(2−ハロゲノシクロプロピル)キノリンカルボン酸誘導体
US4657913A (en) * 1985-04-18 1987-04-14 Warner-Lambert Company Trifluoro- quinoline -3- carboxylic acids and their use as anti-bacterial agents
JPS6259263A (ja) * 1985-09-10 1987-03-14 Kyorin Pharmaceut Co Ltd キノロンカルボン酸誘導体
US4668680A (en) * 1985-12-12 1987-05-26 Warner-Lambert Company 5-amino-6,8-difluoroquinolones as antibacterial agents
US4977154A (en) * 1985-12-12 1990-12-11 Warner-Lambert Company 5-amino and 5-hydroxy-6-fluoroquinolones as antibacterial agents
EP0230053A3 (en) * 1986-01-17 1988-03-30 American Cyanamid Company 7-(substituted)piperazinyl-1-ethyl-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acids
EP0242789A3 (en) * 1986-04-25 1990-09-05 Dainippon Pharmaceutical Co., Ltd. Novel quinoline derivates and processes for preparation thereof
GB8612137D0 (en) * 1986-05-19 1986-06-25 Fujisawa Pharmaceutical Co Quinolone compounds

Also Published As

Publication number Publication date
SU1635898A3 (ru) 1991-03-15
FI87457B (fi) 1992-09-30
EP0375658A1 (en) 1990-06-27
US4795751A (en) 1989-01-03
DK170774B1 (da) 1996-01-15
DK514586A (da) 1987-04-30
DK514586D0 (da) 1986-10-28
AR242031A1 (es) 1993-02-26
JPH0714918B2 (ja) 1995-02-22
DK170593B1 (da) 1995-11-06
EP0375658B1 (en) 1994-08-03
ES2057197T3 (es) 1994-10-16
EP0221463A2 (en) 1987-05-13
YU137191A (sh) 1994-01-20
NZ218089A (en) 1989-03-29
NO864247L (no) 1987-04-30
KR910006806B1 (ko) 1991-09-02
NL970020I2 (nl) 1998-01-05
IL80404A (en) 1990-06-10
JPH0541633B2 (zh) 1993-06-24
YU183586A (en) 1988-04-30
AR243520A1 (es) 1993-08-31
CA1340402C (en) 1999-02-23
JPS62277362A (ja) 1987-12-02
FI87457C (fi) 1993-01-11
FI864299A (fi) 1987-04-30
DE3650018T2 (de) 1995-01-05
DE3650018D1 (de) 1994-09-08
NO170726B (no) 1992-08-17
YU137291A (sh) 1994-01-20
FI864299A0 (fi) 1986-10-23
IL80404A0 (en) 1987-01-30
MY100574A (en) 1990-12-15
DE3680859D1 (de) 1991-09-19
GEP19960467B (en) 1996-05-27
ES2029786T3 (es) 1992-10-01
PT83643B (pt) 1988-10-14
NL300014I2 (nl) 2001-02-01
NO864247D0 (no) 1986-10-23
CN86107491A (zh) 1987-04-29
AU594983B2 (en) 1990-03-22
NL970020I1 (nl) 1997-08-01
LU88596I2 (fr) 1995-07-10
DK25992A (da) 1992-02-28
CN1009930B (zh) 1990-10-10
JPH0543551A (ja) 1993-02-23
PT83643A (en) 1986-11-01
YU46414B (sh) 1993-10-20
AU6427786A (en) 1987-04-30
DE10075028I1 (de) 2000-12-14
DK25992D0 (da) 1992-02-28
SU1598873A3 (ru) 1990-10-07
ATE109472T1 (de) 1994-08-15
DE10075028I2 (de) 2004-01-29
AR243178A1 (es) 1993-07-30
EP0221463A3 (en) 1987-12-02
KR870004019A (ko) 1987-05-06
EP0221463B1 (en) 1991-08-14
HU200452B (en) 1990-06-28
PH22862A (en) 1989-01-19
HUT43839A (en) 1987-12-28
LU90621I2 (fr) 2000-10-09
ATE66210T1 (de) 1991-08-15
GR3002475T3 (en) 1992-12-30
NL300014I1 (nl) 2000-10-02

Similar Documents

Publication Publication Date Title
NO170726C (no) Analogifremgangsmaate ved fremstilling av terapeutisk aktive quinolinderivater
NO171638C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive kinolin-derivater
NO170483C (no) Analogifremgangsmaate ved fremstilling av terapeutisk aktive tetrahydronaftalin- og indanderivater
NO168770C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive benzimidazolderivater
NO170480C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive fenoksyeddiksyre-derivater
NO171506C (no) Analogifremgangsmaate ved fremstilling av terapeutisk aktive adenosin-derivater
NO161370C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive kinolin- og naftyridin-derivater.
NO169493C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive peptid-derivater
NO163406C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive imidazokinolinonderivater.
NO170629C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive dikloranilin-derivater
NO862477D0 (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 2-arylimidazol-derivater.
NO820479L (no) Fremgangsmaate for fremstilling av terapeutisk aktive carbostyrilderivater
NO172343C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive askorbinsyrederivater
NO169014C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive distamycinderivater
NO167026C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive benzimidazolderivater
NO168355C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive benzimidazolderivater
NO162721C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive kinolin- og naftyridinderivater.
NO170482C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive karboksamid-derivater
NO172849C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive tiazol- og oksazol-derivater
NO168299C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive alkansulfonanilid-derivater
NO172489C (no) Analogifremgangsmaate ved fremstilling av terapeutisk aktive imidazolderivater
NO169069C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 3-alkoksy-2-aminopropylaminderivater
NO164020C (no) Analogifremgangsmaate ved fremstilling av terapeutisk aktive fenetanolaminderivater.
NO169007C (no) Analogifremgangsmaate ved fremstilling av terapeutisk aktive uridinderivater
NO167284C (no) Analogifremgangsmaate ved fremstilling av terapeutisk aktive oksazol- og isoksazolderivater.

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees